IMNNImunon Inc. Common Stock
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 Imunon (IMNN) Q2 2026 Earnings Call Transcript Phase 2 ovarian cancer data shows 45.1-month survival versus 30.4 months in control arm. | ||
 Imunon, Inc. Q2 2026 Earnings Call Summary Moby summary of Imunon, Inc.'s Q2 2026 earnings call | ||
 EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study Clinical-stage biotechnology firm Imunon Inc. (NASDAQ:IMNN) on Thursday announced an update on its pivotal Phase 3 OVATION 3 trial evaluating IMNN-001 in newly diagnosed advanced ovarian cancer patients. The company reported site activation and patient enrollment speeds that significantly outpace original forecasts and standard industry benchmarks. Enrollment Rates Exceed Industry Benchmarks The trial progressed from protocol submission to site activation in roughly six months. It reached its fi | ||
 Exclusive: Imunon Says Lead Drug Continues To Show Promise in Advanced Ovarian Cancer Patients Imunon Inc. (NASDAQ:IMNN) on Tuesday reported new preliminary findings from its ongoing Phase 2 minimal residual disease (MRD) translational trial. MRD refers to the small number of cancer cells that remain in the body during or after treatment. The data showed that patients receiving IMNN-001 alongside standard-of-care chemotherapy and bevacizumab demonstrated lower rates of residual disease and higher circulating tumor DNA (ctDNA) clearance than those receiving standard treatment alone. The mu | ||